<SEC-DOCUMENT>0001070081-20-000062.txt : 20200302
<SEC-HEADER>0001070081-20-000062.hdr.sgml : 20200302
<ACCEPTANCE-DATETIME>20200302161255
ACCESSION NUMBER:		0001070081-20-000062
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200302
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200302
DATE AS OF CHANGE:		20200302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		20676937

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k3220.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:66DFC58749D15E51932FA8770F8E2D18,x:c452ef4f2aea46c9a7660cad7a360568-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:ptct="http://www.ptcbio.com/20200302" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="D2020Q1KFiling" name="dei:AmendmentFlag" id="Fact-6D78E7AB917A57E9A2E85AB742DFEA07-wk-Fact-6D78E7AB917A57E9A2E85AB742DFEA07" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="D2020Q1KFiling" name="dei:EntityCentralIndexKey" id="Fact-7071B806971650D9A871936480C7428D-wk-Fact-7071B806971650D9A871936480C7428D">0001070081</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ptct-20200302.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="D2020Q1KFiling">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-02</xbrli:startDate>
			<xbrli:endDate>2020-03-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context></ix:resources></ix:header></div><div><a id="s8C9D4A5186955DC992059C1BE0E4A83D"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d20668387e67-wk-Fact-B18B5CE5D71C551DA44A69A3F623395A" name="dei:DocumentType" contextRef="D2020Q1KFiling"><span style="font-size:18pt;font-weight:bold;">8-K</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported):  </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d20668387e81-wk-Fact-E1EC99EFAD5D58B982D77FDFDA94967F" name="dei:DocumentPeriodEndDate" contextRef="D2020Q1KFiling" format="ixt:datemonthdayyearen">March 2, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:18pt;"><span><ix:nonNumeric id="d20668387e86-wk-Fact-4DE17A506E435C37ABCD3C1ECE5DDE15" name="dei:EntityRegistrantName" contextRef="D2020Q1KFiling"><span style="font-size:18pt;font-weight:bold;">PTC THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact Name of Company as Specified in Charter)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td><td style="width:16px;"></td><td style="width:214px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d20668387e110-wk-Fact-AEA456BE93355868A0C8DE43E59EBBC9" name="dei:EntityIncorporationStateCountryCode" contextRef="D2020Q1KFiling" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d20668387e120-wk-Fact-D7701235B12E5B999ADCEE19496A3180" name="dei:EntityFileNumber" contextRef="D2020Q1KFiling">001-35969</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d20668387e130-wk-Fact-1E8231B4EBAA5AEE9B20F7E6BB3D14B0" name="dei:EntityTaxIdentificationNumber" contextRef="D2020Q1KFiling">04-3416587</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Incorporation)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Commission</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">File Number)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(IRS Employer</span></div><div style="padding-bottom:2px;padding-top:2px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:517px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:141px;"></td><td style="width:114px;"></td><td style="width:33px;"></td><td style="width:228px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d20668387e182-wk-Fact-B6C8ACEE72F7534B8B079F4472FFD4B9" name="dei:EntityAddressAddressLine1" contextRef="D2020Q1KFiling">100 Corporate Court</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d20668387e203-wk-Fact-6F60D21B60C455479FF1C786AC9DA904" name="dei:EntityAddressCityOrTown" contextRef="D2020Q1KFiling">South Plainfield,</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d20668387e208-wk-Fact-9A78F8479897528F82DA5F72541C944D" name="dei:EntityAddressStateOrProvince" contextRef="D2020Q1KFiling">NJ</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d20668387e218-wk-Fact-22A36917E7C955848CF9ABFF6EEC404E" name="dei:EntityAddressPostalZipCode" contextRef="D2020Q1KFiling">07080</ix:nonNumeric></span></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Zip Code)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d20668387e245-wk-Fact-9D90CE8BD8D2508C930BF4BD6197F184" name="dei:CityAreaCode" contextRef="D2020Q1KFiling">(908)</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d20668387e249-wk-Fact-B1B28B305BE95501B8E3DE256639F1A6" name="dei:LocalPhoneNumber" contextRef="D2020Q1KFiling"><span style="font-weight:bold;">222-7000</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">see</span><span style="font-family:inherit;font-size:10pt;"> General Instruction A.2. below):</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d20668387e270-wk-Fact-8E17077AC39A53B1BB113D011F506C35" name="dei:WrittenCommunications" contextRef="D2020Q1KFiling" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d20668387e280-wk-Fact-E2C63CB69F015071BCCFDC73E4D6BC1C" name="dei:SolicitingMaterial" contextRef="D2020Q1KFiling" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d20668387e290-wk-Fact-B95F170873B357FB8F5A42883DFF0862" name="dei:PreCommencementTenderOffer" contextRef="D2020Q1KFiling" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span><ix:nonNumeric id="d20668387e300-wk-Fact-A01D2E79710150F7937320A117BD807D" name="dei:PreCommencementIssuerTenderOffer" contextRef="D2020Q1KFiling" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:5pt;">    </span><span style="font-family:inherit;font-size:10pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:41%;"></td><td style="width:18%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d20668387e342-wk-Fact-08CA5F71A7BB53B8A32A3F88BBC124D7" name="dei:Security12bTitle" contextRef="D2020Q1KFiling">Common Stock, $0.001 par value per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d20668387e347-wk-Fact-D021CCE5738A5FA288AA3E1C3223AC43" name="dei:TradingSymbol" contextRef="D2020Q1KFiling">PTCT</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d20668387e352-wk-Fact-8F82BBB8D17A5620B169A0E100B0E036" name="dei:SecurityExchangeName" contextRef="D2020Q1KFiling" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d20668387e362-wk-Fact-5427347A88EA5F32B51FEE3E7B40B3B9" name="dei:EntityEmergingGrowthCompany" contextRef="D2020Q1KFiling" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;  </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s5F061C49CD685A1AA33F928EA99C24BC"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2.02. &#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 2, 2020, PTC Therapeutics, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter and fiscal year ended December 31, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this Item 2.02.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01. Regulation FD Disclosure.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company will host a conference call on March 2, 2020 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter and fiscal year ended December 31, 2019, as well as other corporate highlights and updates. A slide deck containing highlights of the Company's financial results and corporate updates will be posted on the Company's website.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Directions on how to access the conference call and the slide deck are included in the press release furnished as Exhibit 99.1 hereto.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the&#160;Securities Act of 1933, as amended, or the&#160;Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01. </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statements and Exhibits.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(d) Exhibits</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">99.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit991pressrelease.htm"><span style="font-family:inherit;font-size:10pt;">Press Release, dated March 2, 2020 issued by PTC Therapeutics, Inc.</span></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:6%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PTC Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: March 2, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Emily Hill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Name:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emily Hill</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Title:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit991pressrelease.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB47EED1F8B091B0C44519CE6D1F0EB19"></a></div><div></div><div><br></div><div style="line-height:138%;text-align:right;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">EXHIBIT 99.1</font></div><div style="line-height:138%;text-align:left;"><img src="ptctherapaeuticsfully_image1.gif" alt="ptctherapaeuticsfully_image1.gif" style="height:94px;width:156px;"></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SOUTH PLAINFIELD, N.J. March 2, 2020 </font><font style="font-family:Arial;font-size:10pt;">&#8211; PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2019. </font></div><div style="line-height:138%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;2019 was a year of outstanding execution for PTC. I&#8217;m proud of the progress made in every area of the business,&#8221; said Stuart Peltz, Ph.D., CEO of PTC Therapeutics. &#8220;We&#8217;ve significantly expanded our rare disease portfolio,</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:Arial;font-size:10pt;">strengthened our global commercial engine and added vital gene therapy manufacturing capabilities, all while delivering on our revenue guidance. The innovation in our diverse, multiplatform pipeline continues to create value for stakeholders.&#8221;  </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Key Fourth Quarter and Other Corporate Highlights:  </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Expanding commercial footprint including continued revenue growth</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total revenue for the full year 2019 was $307 million. The Duchenne muscular dystrophy (DMD) franchise, consisting of Translarna&#8482; (ataluren) and Emflaza</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;(deflazacort), continues to grow with 2019 revenue of $291 million. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC continues to leverage its strong Latin American infrastructure to support the launch of multiple products. In 2019, Translarna received approval from the Brazilian health regulatory authority (ANVISA) for ambulatory nmDMD patients 5 years and older. In addition, Tegsedi (inotersen) received ANVISA approval for the treatment of stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). In 2019, PTC established an early access program for patients with Familial Chylomicronemia Syndrome (FCS) in Latin America. PTC anticipates filing for approval of Waylivra</font><font style="font-family:Arial;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></font><font style="font-family:Arial;font-size:10pt;">&#32;(volanesorsen) for the treatment of FCS from ANVISA in 2H 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Real-world data from the Translarna STRIDE registry demonstrated that boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) treated with Translarna and standard of care, preserved the ability to walk for 3.5 years longer than compared with those in a matched natural history cohort. Importantly, pulmonary function was also preserved in those treated with Translarna. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A recent </font><a style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;" href="#"><font style="font-family:Arial;font-size:10pt;color:#000000;text-decoration:none;">publication</font></a><font style="font-family:Arial;font-size:10pt;">&#32;on Emflaza adds to the growing body of evidence showing its relative benefit and supports the advantage of switching from prednisone to Emflaza. The data in the publication demonstrated that patients treated with Emflaza had better ambulatory function and were able to walk longer, had a lower risk of scoliosis, greater percentage lean body mass and lower weight than patients treated with prednisone. </font><font style="font-family:Arial;font-size:10pt;font-style:italic;">&#32;</font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Positive pivotal trials for risdiplam support planned global launch in broad range of SMA patient types</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Following the U.S. Food and Drug Association&#8217;s (FDA) acceptance of the New Drug Application (NDA) for risdiplam, a Prescription Drug User Fee Act (PDUFA) date for risdiplam has been set for May 24, 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Roche&#8217;s Marketing Authorization Application (MAA) filing with the European Medicines Agency (EMA) for risdiplam is expected mid-year 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Data from part 2 of the FIREFISH trial will be presented during the American Academy of Neurology (AAN) 2020 Annual Meeting, from April 25 to May 1, 2020. </font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PTC gene therapy platform continues to make progress with regulatory filings and long-term lease of manufacturing facility </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:10pt;">In January 2020, the EMA accepted the MAA for the potential approval of PTC-AADC for the treatment of Aromatic l-amino acid decarboxylase </font><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;color:#222222;">(</font><font style="font-family:Arial;font-size:10pt;">AADC) deficiency. PTC expects the Committee for Medicinal Products for Human Use (CHMP) opinion by year end 2020.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC expects to submit a Biologics License Application (BLA)</font><font style="font-family:Arial;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:Arial;font-size:10pt;">to the FDA in 2Q 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC continues to anticipate that more than 300 global</font><font style="font-family:Arial;font-size:10pt;font-style:italic;">, </font><font style="font-family:Arial;font-size:10pt;">addressable AADC patients will be identified by launch. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:130%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:130%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2019, PTC leased a state-of-the-art biologics manufacturing facility with supporting research and operations buildings in N.J. PTC expects manufacturing at this facility to begin in 2020.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Continued progress with PTC&#8217;s multi-platform, multi-product pipeline</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Phase 2 STAR trial in patients with nonsense mutation aniridia evaluating the effect of ataluren did not meet its primary endpoint of Maximum Reading Speed as measured by MNREAD. The results did show a trend in favor of ataluren and the results will be discussed with experts in the coming weeks, after which a decision will be made on a path forward for the program in this indication.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Topline data from the U.S. study to assess dystrophin levels in subjects with nmDMD after treatment with ataluren are expected in 2Q 2020. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2019, PTC declared a development candidate in its Huntington&#8217;s Disease program. The compound is currently in GLP safety toxicology studies and PTC expects to initiate a clinical trial by the end of the year. The Huntington&#8217;s Disease program was developed through PTC&#8217;s alternative splicing platform. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In 2020, PTC plans to initiate three clinical trials in two compounds that regulate inflammation and oxidative stress from its Bio-e (redox) platform. PTC acquired the Bio-e platform through an acquisition of assets from BioElectron Technology Corporation in 2019.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:10pt;">Potential registrational trial of PTC743 in patients with Mitochondrial Epilepsy (MEDS) expected to begin in 2Q 2020. MEDS is estimated to affect 5,000-6,000 patients in the U.S. and E.U. combined.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:10pt;">Potential registrational trial of PTC743 in patients with Friedreich Ataxia (FA) expected to begin in 3Q 2020. This is anticipated to be complementary to PTC-FA, a gene therapy candidate for the treatment of FA, which is expected to enter the clinic in 3Q 2020. FA is estimated to affect 25,000 patients worldwide.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:12pt;padding-left:24px;"><font style="font-family:inherit;font-size:12pt;">o</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:10pt;">PTC857 will enter into a Phase 1 healthy volunteer study in 3Q 2020. The first indication for PTC857 is planned to be GBA Parkinson&#8217;s disease based on strong pre-clinical rationale. This condition affects approximately 50,000-90,000 patients in the U.S.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Additional updates on PTC&#8217;s platforms and pipeline will be provided at PTC&#8217;s Analyst Day on June 16, 2020.</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Fourth Quarter and Full-year 2019 Financial Highlights:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Total revenues were $96.5 million for the fourth quarter of 2019, compared to $86.3 million for the fourth quarter of 2018. Total revenues were $307 million for the full year 2019, compared to $264.7 million for the full year 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Translarna net product revenues were $48.4 million for the fourth quarter of 2019, compared to $56 million for the fourth quarter of 2018. Translarna net product revenues were $190 million for the full year 2019, compared to $171 million for the full year 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Emflaza net product revenues were $32.7 million for the fourth quarter of 2019, compared to $29.8 million for the fourth quarter of 2018. Emflaza net product revenues were $101 million for the full year 2019, compared to $92 million for the full year 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GAAP R&amp;D expenses were $81.8 million for the fourth quarter of 2019, compared to $53.6 million for the fourth quarter of 2018. GAAP R&amp;D expenses were $257.4 million for the full year 2019, compared to $172 million for the full year 2018. The increase in R&amp;D expenses reflects costs associated with advancing the gene therapy platform, increased investment in research programs, advancement of the clinical pipeline and the upfront $10M payment for the acquisition of the BioElectron assets.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-GAAP R&amp;D expenses were $76.2 million for the fourth quarter of 2019, excluding $5.6 million in non-cash, stock-based compensation expense, compared to $49.7 million for the fourth quarter of 2018, excluding $4 million in non-cash, stock-based compensation expense. Non-GAAP R&amp;D expenses were $236.6 million for the full year 2019, excluding $20.8 million in non-cash, stock-based compensation expense, compared to $155.9 million for the full year 2018, excluding $16.1 million in non-cash, stock-based compensation expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GAAP SG&amp;A expenses were $63.5 million for the fourth quarter of 2019, compared to $48.7 million for the fourth quarter of 2018. GAAP SG&amp;A expenses were $202.5 million for the full year 2019, compared to $153.6 million for the full year 2018. The increase in SG&amp;A expenses was primarily due to continued investment to support our commercial activities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Non-GAAP SG&amp;A expenses were $57.7 million for the fourth quarter of 2019, excluding $5.8 million in non-cash, stock-based compensation expense, compared to $44.2 million for the fourth quarter of 2018, excluding $4.5 million in non-cash, stock-based compensation expense. Non-GAAP SG&amp;A expenses were $181.2 million for the full year 2019, excluding $21.3 million in non-cash, stock-based compensation expense, compared to $136.4 million for the full year 2018, excluding $17.2 million in non-cash, stock-based compensation expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Change in the fair value of deferred and contingent consideration was $12.4 million for the quarter ended December 31, 2019, compared to $19.3 million for the quarter ended December 31, 2018. Change in the fair value of deferred and contingent consideration was $48.4 million for the year ended December 31, 2019, compared to $19.3 million for the year ended December 31, 2018. The change is related to the fair valuation of the potential future consideration to be paid to former equity holders of Agilis, as a result of our merger with Agilis which closed in August 2018. Changes in the fair value were due to the re-calculation of discounted cash flows for the passage of time and changes to certain other estimated assumptions.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Net loss was $77.7 million for the fourth quarter of 2019, compared to net loss of $48.3 million for the fourth quarter of 2018. Net loss was $251.6 million for the full year 2019, compared to net loss of $128.1 million for the full year 2018.</font></div></td></tr></table><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cash, cash equivalents, and marketable securities was $686.6 million at December 31, 2019, compared to $227.6 million at December 31, 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Shares issued and outstanding as of December 31, 2019 were 61,935,870.</font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">PTC Reaffirms Full Year 2020 Guidance as Follows</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC anticipates full year DMD franchise net product revenues to be between $320 and $340 million.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC anticipates GAAP R&amp;D and SG&amp;A expense for the full year 2020 to be between $610 and $640 million.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:0px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC anticipates Non-GAAP R&amp;D and SG&amp;A expense for the full year 2020 to be between $545 and $575 million, excluding estimated non-cash, stock-based compensation expense of approximately $65 million.</font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Non-GAAP Financial Measures:</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In this press release, the financial results and financial guidance of PTC are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. In particular, the non-GAAP financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.</font></div><div style="line-height:130%;padding-bottom:10px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Consolidated Statements of Operations</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(In thousands, except share and per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended     December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Twelve Months Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Revenues:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">81,407</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">85,833</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">291,306</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">263,005</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Collaboration and grant revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15,052</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15,674</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,729</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,459</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">86,338</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">306,980</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">264,734</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Operating expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cost of product sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,542</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,761</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,135</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,670</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amortization of acquired intangible asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,973</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,062</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">27,650</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,877</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Research and development (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">81,831</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">53,647</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">257,452</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">171,984</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Selling, general and administrative (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">63,497</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">48,666</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">202,541</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">153,548</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Change in the fair value of deferred and contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,340</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">48,360</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,340</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">169,243</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">131,476</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">548,138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">380,419</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(72,784</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(45,138</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(241,158</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(115,685</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Interest expense, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5,463</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,248</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12,491</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12,554</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other expense (income), net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,214</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(937</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,723</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loss before income tax expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(67,033</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(49,323</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(239,926</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(128,110</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Income tax (expense) benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10,644</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">993</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(77,677</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(48,330</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(251,576</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(128,081</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Weighted-average shares outstanding:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:12px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Basic and diluted (in shares)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56,570,002</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50,331,914</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">58,863,185</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">46,576,313</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss per share&#8212;basic and diluted (in dollars per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1.37</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(0.96</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4.27</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2.75</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(1) Research and development reconciliation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">GAAP research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">81,831</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">53,647</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">257,452</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">171,984</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Less: share-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,645</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20,836</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,096</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-GAAP research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76,186</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49,661</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">236,616</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">155,888</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(2) Selling, general and administrative reconciliation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">GAAP selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">63,497</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">48,666</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">202,541</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">153,548</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Less: share-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,821</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,492</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,298</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">17,156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Non-GAAP selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">57,676</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">44,174</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">181,243</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">136,392</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Summary Consolidated Balance Sheets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands, except share data)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">686,563</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">227,586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,623,782</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,119,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">313,859</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">153,014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total deferred revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11,657</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,029,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">768,495</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Total stockholders' equity (61,935,870 and 50,606,147 common shares issued and outstanding at December 31, 2019 and December 31, 2018 respectively)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">594,330</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">350,727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,623,782</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1,119,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:100%;text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">PTC Therapeutics, Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reconciliation of GAAP to Non-GAAP Projected Full Year 2020 R&amp;D and SG&amp;A Expense</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Low End of Range</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">High End of Range</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Projected GAAP R&amp;D and SG&amp;A Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">610,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">640,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Less: projected non-cash, stock-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">65,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">65,000</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Projected non-GAAP R&amp;D and SG&amp;A expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">545,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">575,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Today's Conference Call and Webcast Reminder: </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Today's conference call will take place at 4:30 pm ET and can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 1732477. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. The accompanying slide presentation will be posted on the investor relations section of the PTC website. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">About PTC Therapeutics, Inc.</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">For More Information:</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Investors:</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Alex Kane</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">+1 (908) 912-9643</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">akane@ptcbio.com</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Media:</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Jane Baj</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">+1 (908) 912-9167</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">jbaj@ptcbio.com</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Forward Looking Statements:</font></div><div style="line-height:156%;padding-bottom:18px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "Full Year 2020 Guidance", including with respect to (i) 2020 net product revenue guidance and (ii) 2020 GAAP and non-GAAP R&amp;D and SG&amp;A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions and manufacturing capabilities; advancement of PTC's joint collaboration program in SMA, including any potential regulatory submissions, commercialization or royalty or milestone payments; PTC's expectations with respect to the licensing, regulatory submissions and commercialization of its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.</font></div><div style="line-height:156%;padding-bottom:18px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions and potential approvals, manufacturing capabilities and the potential financial impact and benefits of its leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; the enrollment, conduct, and results of studies under the SMA collaboration and events during, or as a result of, the studies that could delay or prevent further development under the program, including any potential regulatory submissions and potential commercialization with regards to risdiplam; PTC's ability to complete a dystrophin study necessary to support a re-submission of its Translarna NDA for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) to the&#160;FDA, and PTC's ability to perform any necessary additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the&#160;European Medicines Agency&#160;(EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD </font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:156%;padding-bottom:18px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the commercialization of Tegsedi and Waylivra; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#8217;s products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of the lease agreement for its leased biologics manufacturing facility; PTC's ability to satisfy its obligations under the terms of the senior secured term loan facility with MidCap Financial; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the&#160;SEC. You are urged to carefully consider all such factors.</font></div><div style="line-height:156%;padding-bottom:18px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra or risdiplam.</font></div><div style="line-height:156%;padding-bottom:18px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;background-color:#ffffff;">The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ptct-20200302.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ptcbio.com/20200302" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ptct="http://www.ptcbio.com/20200302" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200302_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200302_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200302_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ptct-20200302_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CoverPageDocument" roleURI="http://www.ptcbio.com/role/CoverPageDocument">
        <link:definition>0001000 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="ptct_CoverpageAbstract" name="CoverpageAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>ptct-20200302_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200302.xsd#CoverPageDocument" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>ptct-20200302_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200302.xsd#CoverPageDocument" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ptct-20200302_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ptct_CoverpageAbstract_9F9EA1EE689BFAAE34CB12EB78562B6C_label_en-US" xlink:label="lab_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:label id="lab_ptct_CoverpageAbstract_9F9EA1EE689BFAAE34CB12EB78562B6C_documentation_en-US" xlink:label="lab_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">cover page [Abstract]</link:label>
    <link:loc xlink:href="ptct-20200302.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="lab_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C4517B94B84052FE32B512EB785B4079_terseLabel_en-US" xlink:label="lab_dei_DocumentType_17DBFB2C62EA5CAC80E64E0F1F304E70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C4517B94B84052FE32B512EB785B4079_label_en-US" xlink:label="lab_dei_DocumentType_17DBFB2C62EA5CAC80E64E0F1F304E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_17DBFB2C62EA5CAC80E64E0F1F304E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_17DBFB2C62EA5CAC80E64E0F1F304E70" xlink:to="lab_dei_DocumentType_17DBFB2C62EA5CAC80E64E0F1F304E70" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_0E83231B49EC1FE81A3612EB785BBF36_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_FFCF1EFD11E05E2092C7B33D745B86BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_0E83231B49EC1FE81A3612EB785BBF36_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_FFCF1EFD11E05E2092C7B33D745B86BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_FFCF1EFD11E05E2092C7B33D745B86BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_FFCF1EFD11E05E2092C7B33D745B86BA" xlink:to="lab_dei_DocumentPeriodEndDate_FFCF1EFD11E05E2092C7B33D745B86BA" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_C596222BA97ACDF1A10B12EB785B6491_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_EB40FA03341E5ECD99F28C9272DC0F84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_C596222BA97ACDF1A10B12EB785B6491_label_en-US" xlink:label="lab_dei_EntityRegistrantName_EB40FA03341E5ECD99F28C9272DC0F84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_EB40FA03341E5ECD99F28C9272DC0F84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_EB40FA03341E5ECD99F28C9272DC0F84" xlink:to="lab_dei_EntityRegistrantName_EB40FA03341E5ECD99F28C9272DC0F84" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_F7E76C8EB6B2A429763012EB785A74D9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_ABC460F0A2D75157BBB7E0BB0865B50F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_F7E76C8EB6B2A429763012EB785A74D9_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_ABC460F0A2D75157BBB7E0BB0865B50F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ABC460F0A2D75157BBB7E0BB0865B50F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_ABC460F0A2D75157BBB7E0BB0865B50F" xlink:to="lab_dei_EntityIncorporationStateCountryCode_ABC460F0A2D75157BBB7E0BB0865B50F" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_E7EA6DB36C0F561D720212EB7B8131CB_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_682EE31D178F56A18DE6C6D5A6FBEFD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contained File Information, File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_E7EA6DB36C0F561D720212EB7B8131CB_label_en-US" xlink:label="lab_dei_EntityFileNumber_682EE31D178F56A18DE6C6D5A6FBEFD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_682EE31D178F56A18DE6C6D5A6FBEFD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_682EE31D178F56A18DE6C6D5A6FBEFD0" xlink:to="lab_dei_EntityFileNumber_682EE31D178F56A18DE6C6D5A6FBEFD0" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E3123AAC3A41E48A1A9712EB785C4170_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_FE4A44E5BB805691B5D4192EB78700CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_E3123AAC3A41E48A1A9712EB785C4170_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_FE4A44E5BB805691B5D4192EB78700CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_FE4A44E5BB805691B5D4192EB78700CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_FE4A44E5BB805691B5D4192EB78700CE" xlink:to="lab_dei_EntityTaxIdentificationNumber_FE4A44E5BB805691B5D4192EB78700CE" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_DDE7C637B1DE93E587D112EB785A5F77_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_E8344DC935AA55ABA46D5D4AC16EDDB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_DDE7C637B1DE93E587D112EB785A5F77_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_E8344DC935AA55ABA46D5D4AC16EDDB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_E8344DC935AA55ABA46D5D4AC16EDDB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_E8344DC935AA55ABA46D5D4AC16EDDB0" xlink:to="lab_dei_EntityAddressAddressLine1_E8344DC935AA55ABA46D5D4AC16EDDB0" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_592048EF44AAE536846012EB785C0C8F_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_A9518E675C4E512B8FB124526A78AC41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_592048EF44AAE536846012EB785C0C8F_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_A9518E675C4E512B8FB124526A78AC41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_A9518E675C4E512B8FB124526A78AC41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_A9518E675C4E512B8FB124526A78AC41" xlink:to="lab_dei_EntityAddressCityOrTown_A9518E675C4E512B8FB124526A78AC41" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_D134AAF98F8970CE5DA412EB785C86A7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_2D6AE08B99295599AAF573852A785CBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_D134AAF98F8970CE5DA412EB785C86A7_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_2D6AE08B99295599AAF573852A785CBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_2D6AE08B99295599AAF573852A785CBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_2D6AE08B99295599AAF573852A785CBC" xlink:to="lab_dei_EntityAddressStateOrProvince_2D6AE08B99295599AAF573852A785CBC" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_3A88E27A4B92A3EB914412EB785C141A_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_786E8FE0A5A55F589602F0B5832F31F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3A88E27A4B92A3EB914412EB785C141A_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_786E8FE0A5A55F589602F0B5832F31F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_786E8FE0A5A55F589602F0B5832F31F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_786E8FE0A5A55F589602F0B5832F31F1" xlink:to="lab_dei_EntityAddressPostalZipCode_786E8FE0A5A55F589602F0B5832F31F1" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_1AEC18E92172051E527C12EB785C731C_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_A6E2433E910B552BB93A8AE7F7CBFE0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_1AEC18E92172051E527C12EB785C731C_label_en-US" xlink:label="lab_dei_CityAreaCode_A6E2433E910B552BB93A8AE7F7CBFE0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_A6E2433E910B552BB93A8AE7F7CBFE0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_A6E2433E910B552BB93A8AE7F7CBFE0C" xlink:to="lab_dei_CityAreaCode_A6E2433E910B552BB93A8AE7F7CBFE0C" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_5A3B1F056BEACDAA3FC312EB785D41F0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_827996B95F075ACAA99FA7646D66130C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_5A3B1F056BEACDAA3FC312EB785D41F0_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_827996B95F075ACAA99FA7646D66130C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_827996B95F075ACAA99FA7646D66130C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_827996B95F075ACAA99FA7646D66130C" xlink:to="lab_dei_LocalPhoneNumber_827996B95F075ACAA99FA7646D66130C" xlink:type="arc" />
    <link:label id="lab_dei_WrittenCommunications_DCE23CB8DE201B588EA312EB785DBCD6_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications_93FB0B06F63750AFA996F3A7DB8E85F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_DCE23CB8DE201B588EA312EB785DBCD6_label_en-US" xlink:label="lab_dei_WrittenCommunications_93FB0B06F63750AFA996F3A7DB8E85F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_93FB0B06F63750AFA996F3A7DB8E85F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications_93FB0B06F63750AFA996F3A7DB8E85F8" xlink:to="lab_dei_WrittenCommunications_93FB0B06F63750AFA996F3A7DB8E85F8" xlink:type="arc" />
    <link:label id="lab_dei_SolicitingMaterial_760B757C59FA279516CD12EB785D2D23_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial_6770EC66B42F53569B417CB70597369C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_760B757C59FA279516CD12EB785D2D23_label_en-US" xlink:label="lab_dei_SolicitingMaterial_6770EC66B42F53569B417CB70597369C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_6770EC66B42F53569B417CB70597369C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial_6770EC66B42F53569B417CB70597369C" xlink:to="lab_dei_SolicitingMaterial_6770EC66B42F53569B417CB70597369C" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementTenderOffer_344CB19EC791150E96E912EB785DB49A_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_29CAD3DF80BF5764B7FC1204FDF50F4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_344CB19EC791150E96E912EB785DB49A_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer_29CAD3DF80BF5764B7FC1204FDF50F4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_29CAD3DF80BF5764B7FC1204FDF50F4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer_29CAD3DF80BF5764B7FC1204FDF50F4B" xlink:to="lab_dei_PreCommencementTenderOffer_29CAD3DF80BF5764B7FC1204FDF50F4B" xlink:type="arc" />
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_59137A62338E67AAB28C12EB785D6654_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_E566DB1631B25C7AA2C517174CAB5A9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_59137A62338E67AAB28C12EB785D6654_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer_E566DB1631B25C7AA2C517174CAB5A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_E566DB1631B25C7AA2C517174CAB5A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer_E566DB1631B25C7AA2C517174CAB5A9B" xlink:to="lab_dei_PreCommencementIssuerTenderOffer_E566DB1631B25C7AA2C517174CAB5A9B" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_001777A8A6AF6538D2A412EB7859C521_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_75852B8A27655A28868D159FE62829EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_001777A8A6AF6538D2A412EB7859C521_label_en-US" xlink:label="lab_dei_Security12bTitle_75852B8A27655A28868D159FE62829EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_75852B8A27655A28868D159FE62829EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_75852B8A27655A28868D159FE62829EA" xlink:to="lab_dei_Security12bTitle_75852B8A27655A28868D159FE62829EA" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_B80EC5FA2E5A9146AE5012EB785D4F73_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_35FE5874B8165B2B95345EC73623318C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_B80EC5FA2E5A9146AE5012EB785D4F73_label_en-US" xlink:label="lab_dei_TradingSymbol_35FE5874B8165B2B95345EC73623318C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_35FE5874B8165B2B95345EC73623318C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_35FE5874B8165B2B95345EC73623318C" xlink:to="lab_dei_TradingSymbol_35FE5874B8165B2B95345EC73623318C" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_BD2611354DB294EA551E12EB785E1FBF_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_145FD1CC82895E68BCA913E58D622362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_BD2611354DB294EA551E12EB785E1FBF_label_en-US" xlink:label="lab_dei_SecurityExchangeName_145FD1CC82895E68BCA913E58D622362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_145FD1CC82895E68BCA913E58D622362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_145FD1CC82895E68BCA913E58D622362" xlink:to="lab_dei_SecurityExchangeName_145FD1CC82895E68BCA913E58D622362" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_273F49BF87E829DB473712EB785EE2F6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7726B2AB9DCA57EFABB70A06AF3577FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_273F49BF87E829DB473712EB785EE2F6_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_7726B2AB9DCA57EFABB70A06AF3577FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7726B2AB9DCA57EFABB70A06AF3577FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_7726B2AB9DCA57EFABB70A06AF3577FD" xlink:to="lab_dei_EntityEmergingGrowthCompany_7726B2AB9DCA57EFABB70A06AF3577FD" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_FB2DC3B7252F22BA459212EB785B3EDD_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_71AB3AD361AA5549994E2F893A88AC6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_FB2DC3B7252F22BA459212EB785B3EDD_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_71AB3AD361AA5549994E2F893A88AC6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_71AB3AD361AA5549994E2F893A88AC6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_71AB3AD361AA5549994E2F893A88AC6C" xlink:to="lab_dei_EntityCentralIndexKey_71AB3AD361AA5549994E2F893A88AC6C" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_32233D09D70BAE14723212EB785B60EE_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_167B7FE79E635308A5C01C45711CD18C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_32233D09D70BAE14723212EB785B60EE_label_en-US" xlink:label="lab_dei_AmendmentFlag_167B7FE79E635308A5C01C45711CD18C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_167B7FE79E635308A5C01C45711CD18C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_167B7FE79E635308A5C01C45711CD18C" xlink:to="lab_dei_AmendmentFlag_167B7FE79E635308A5C01C45711CD18C" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ptct-20200302_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.ptcbio.com/role/CoverPageDocument" xlink:href="ptct-20200302.xsd#CoverPageDocument" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.ptcbio.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:href="ptct-20200302.xsd#ptct_CoverpageAbstract" xlink:label="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_17DBFB2C62EA5CAC80E64E0F1F304E70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_DocumentType_17DBFB2C62EA5CAC80E64E0F1F304E70" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_FFCF1EFD11E05E2092C7B33D745B86BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_DocumentPeriodEndDate_FFCF1EFD11E05E2092C7B33D745B86BA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_EB40FA03341E5ECD99F28C9272DC0F84" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityRegistrantName_EB40FA03341E5ECD99F28C9272DC0F84" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ABC460F0A2D75157BBB7E0BB0865B50F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ABC460F0A2D75157BBB7E0BB0865B50F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_682EE31D178F56A18DE6C6D5A6FBEFD0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityFileNumber_682EE31D178F56A18DE6C6D5A6FBEFD0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_FE4A44E5BB805691B5D4192EB78700CE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityTaxIdentificationNumber_FE4A44E5BB805691B5D4192EB78700CE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_E8344DC935AA55ABA46D5D4AC16EDDB0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityAddressAddressLine1_E8344DC935AA55ABA46D5D4AC16EDDB0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_A9518E675C4E512B8FB124526A78AC41" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityAddressCityOrTown_A9518E675C4E512B8FB124526A78AC41" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_2D6AE08B99295599AAF573852A785CBC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityAddressStateOrProvince_2D6AE08B99295599AAF573852A785CBC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_786E8FE0A5A55F589602F0B5832F31F1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityAddressPostalZipCode_786E8FE0A5A55F589602F0B5832F31F1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_A6E2433E910B552BB93A8AE7F7CBFE0C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_CityAreaCode_A6E2433E910B552BB93A8AE7F7CBFE0C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_827996B95F075ACAA99FA7646D66130C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_LocalPhoneNumber_827996B95F075ACAA99FA7646D66130C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_dei_WrittenCommunications_93FB0B06F63750AFA996F3A7DB8E85F8" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_WrittenCommunications_93FB0B06F63750AFA996F3A7DB8E85F8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_dei_SolicitingMaterial_6770EC66B42F53569B417CB70597369C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_SolicitingMaterial_6770EC66B42F53569B417CB70597369C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_dei_PreCommencementTenderOffer_29CAD3DF80BF5764B7FC1204FDF50F4B" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_PreCommencementTenderOffer_29CAD3DF80BF5764B7FC1204FDF50F4B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_E566DB1631B25C7AA2C517174CAB5A9B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_E566DB1631B25C7AA2C517174CAB5A9B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_75852B8A27655A28868D159FE62829EA" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_Security12bTitle_75852B8A27655A28868D159FE62829EA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_35FE5874B8165B2B95345EC73623318C" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_TradingSymbol_35FE5874B8165B2B95345EC73623318C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_145FD1CC82895E68BCA913E58D622362" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_SecurityExchangeName_145FD1CC82895E68BCA913E58D622362" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_7726B2AB9DCA57EFABB70A06AF3577FD" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityEmergingGrowthCompany_7726B2AB9DCA57EFABB70A06AF3577FD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_71AB3AD361AA5549994E2F893A88AC6C" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_EntityCentralIndexKey_71AB3AD361AA5549994E2F893A88AC6C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_167B7FE79E635308A5C01C45711CD18C" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ptct_CoverpageAbstract_1447F5EF0EBC5B01892DCAE66F7E6F2B" xlink:to="loc_dei_AmendmentFlag_167B7FE79E635308A5C01C45711CD18C" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ptctherapaeuticsfully_image1.gif
<TEXT>
begin 644 ptctherapaeuticsfully_image1.gif
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E,4455V2Q11=?A#%&&6>DL48;;\0Q1QUWY+%''W\$,DCZ @( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M.%*"IFZ ]<O$<)J'#JZ !4887?HNH%F)I?HGMG2 G9-SLFMJFJ9Z:DLN[]#
MV]/C2UFWLF,B-6K,OY*5= JX99?)K^W=_>Z!]8(+7O&VXF+7;&0C9'O[OKC^
M\+L*.V_LWOYCXXM@W\&ON^B_ %!+ P04    " ";@6)0F5R<(Q &  "<)P
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M)J$)<IQHNS"BL2P$$8WR1BUX:S2?-:PS%L/35B#E2SC"K\T5]]B0F/.Q#L=
M@HK5]*M>S'A<T0G\1[;(?:"]OXF66'$Q^&'PJ]&S_VTP",\.&C'._MAL]3T[
MMU9.[Z5HM8*XEM\63&XL6&1\K4,ZX\2KYPLWI?( .$HNX%!41^2[X_8,(ZZW
M:6QNU9S^AYK_]CZWH,%Q>13MK_Z_O,M_HI@MW7-HT:L&W5!2#D*BT(O&3M0U
M1'GAA<SIE_#PRJL^V?O4TR,O_0-^Q>_GUM#P0>)S6/$<S.EN?PHO3?*P99TW
MBISN]F>HQ:#>S@7WOT3Q U!+ P04    " ";@6)0V_W$-3T!   P @  #P
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M:W1-1X>LX'LQYT4,CQT>7S%1]_276<]>@C"MA[_)1/TUP.K795]02P,$%
M  @ FX%B4 N/V ,A 0  5P0  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULM51-
M3\,P#/TK4Z]HS>#  6V[ %>8!'\@)&X;-5^RO=']>]QN0V(J8FC;)8GS[/=>
M$BOS]VT&FG3!1UH4#7-^4(I, T%3F3)$0:J$0;.$6*NL3:MK4'>SV;TR*3)$
MGG+/42SG3U#IM>?)XVZ_IUX4.F?OC&:7HMI$>T0ZW1.6"'[(H<9ENI&$8O+<
M"0O)WJ(0E IU@L)Q81]+W>L&$)V%?UE+5>4,V&3604I*R@C:4@/ P9?4: 3[
MQNABO?>[TL@O.@BQZKSZD5!>SP=O/8P;&)!+*K.T!8Q)#<!NO#U+\- -)B%,
M,PJ*[$:.)Y96@I+J$R]Y1.A;QX(]25RHK_>PGPG;83UVX=\@J6$Z[];_:'29
MRZ!=_,W(1TKM05\-_\GR"U!+ 0(4 Q0    ( )N!8E ?(\\#P    !,"   +
M              "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )N!8E G
MZ(<.@@   +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @ FX%B4*?'\N/N    *P(  !$              ( !F0$
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ FX%B4)E<G",0!@  G"<
M !,              ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " ";@6)0NC$RKZ,"  "7"P  &               @ 'W"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ FX%B4/<IM6UE @  WP4
M !0              ( !T L  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#
M%     @ FX%B4+JA.8K7 0  ,@8   T              ( !9PX  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " ";@6)0V_W$-3T!   P @  #P
M    @ %I$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ FX%B4/_ )@B]
M    A0(  !H              ( !TQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ FX%B4 N/V ,A 0  5P0  !,
M ( !R!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      H "@"  @  &A0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>10
<FILENAME>0001070081-20-000062-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-20-000062-xbrl.zip
M4$L#!!0    ( )N!8E!J5I3?5!D  *>F   +    83AK,S(R,"YH=&WM/6MS
MHTB2GW=_19WV=L\=84D\!:B[O8$ S?AFVNVS/3$;]PU!R6(; 0/(C_OUEUF
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M:* \9QG-KT0% P3QTS+0L1N!D6B@ A_$JV8U[.-7LP#WJS_$=%W](2Q-<5+
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M" ?4O,<SZ,#C-JPP\S@EEW/? ;HSLG]V?'F XUU:]J;L$TQW;G-H$< R@78
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MR"]_D2@?W45YK[UIO '<N:<R;*K3[QN#U;+6#>)!I;[>HGA$K:\9 ,T*2X&
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M',74Q]X.2\H,=6* J@LVO99Z+?5:ZK6LZEQWRK PK6U8%A]HQ&T")@1QN)N
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M.>0#=:EO,W(Y8RR.7FY\>^_WN4_BF4@BZCM 'O;59D&LJH4(C(T>E/VL%VW
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M.5=",>48Q2)%]_<F2$-1\./ 6PUS*BC2PN\=&*4*"<%$"OUFPC(DD+1]?W-
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MJO;I[*OIO)G1\3B8278+)C"*F"7& J,T40!R@6(M#:66&6J1>NIDWBRQI7_
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MBVUJ"3)@1OPT@KV&_R)=G\P##-E5=M\/>@$7]N@DUD0RB@Q1B@-"!50DCJ!
M1C'. -"F!3'H@(G1#9R]LD3.YR$NU<-7V,<Y>) A.^03PW$4Q5I@(B4A4LDH
M,#Z.I(;4Q+%JDS;8@-G1'LI?P0P=+C_XB_*V> DOODDG4A#(#65$!Z9#I+A5
M$$4$4<FXU!%LP0H^?%;\-)"_@A.;JN>#/_/EEZSIO[^ &,]4$A13:0!70B!!
MB!!26L(P)RA,BFBE6[!##)\=[=#\%10Y*ZLZS?_-5C_<I.Q22!BGAEL#) EI
MT!(N*$ 6*,(QLAC:-LD#@N'SHPV8/;&C26C2N_0 '[X7220U*,+8"!@\)4@I
M@267AEFF59A+FP0!A]G8; %?3S%O3J+SL^NR.+P/?2Z6<,2$H$H0"QB16DHA
MK&0TU$*40MPN]L/L9[:$L*?X?_)97;M"E\OE3?&P!:KVD&"G;"*P54 !:BEF
M!$@;ID$MEBQ6W'!B>1LF#+.;V06./='AO,RS659GQ>)=*%]\EN9[N+ MF%#&
M@-&4J@A9@L.F644PI#(&B&"8BE8I89C=RM8@]L2",^\:<KI0MVZ.X9K37O_A
MZFKO\K!?(4%"RQC'E@,5"EX:*68U1""RL27 1B\ZM=W'BF%V+#L#\]>PXZ2J
M;IS_WQS94DL,H316D&*H$-%,2J0)9)!%6BHB12NF#+.%V3&D?:TI;G835KP[
MB"XOLCK?M[5X+I8P$G;'BDO$*"$2<4YY#(FPAB*.A&ES8@Z'V;1L"6%/\;_P
M:?-B[?G=\K+<5TX\D4DPL89P%BD.*5$HE,@X(D:'!1!A#'FK2F*8C<DV^/7\
MLS?KV75:+-R!ER1VB088B(VAUAQQ00SE2DL!<9A73!$*,VE#@F'V'SN L=>^
MHUDZOP@L_=.7M_5U6+E6:7%WL/&X4R-A#%&%I!(!$<*,E2K4QQ)0:3%AS,9M
M7J4:<N>Q"S1[)8@.:/@T/PD%S/HO=Y@:SV03!J7"H3BFL#F6BX00D4&6-STU
M+C5MLV:@838CN\"Q)SK(4,[.FY+6YNEB#PV>R"20LK 9,DP8B@D&7!(-H(X(
M@U#'[4H&-,Q^9!O\OH7]S70+NM-PX^VKAP?-1_,?1F]?_0=02P$"% ,4
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64$L%!@     '  < S $  '1C      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6605785472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Mar. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ptct_CoverpageAbstract', window );"><strong>cover page [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  02,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Contained File Information, File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Corporate Court<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South Plainfield,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ptct_CoverpageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>cover page [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ptct_CoverpageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ptct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="a8k3220.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="a8k3220.htm">a8k3220.htm</File>
    <File>exhibit991pressrelease.htm</File>
    <File>ptct-20200302.xsd</File>
    <File>ptct-20200302_cal.xml</File>
    <File>ptct-20200302_def.xml</File>
    <File>ptct-20200302_lab.xml</File>
    <File>ptct-20200302_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "a8k3220.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "ptct-20200302_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ptct-20200302_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "a8k3220.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ptct-20200302_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ptct-20200302_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ptct-20200302.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20200302",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a8k3220.htm",
      "contextRef": "D2020Q1KFiling",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page Document",
     "role": "http://www.ptcbio.com/role/CoverPageDocument",
     "shortName": "Cover Page Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a8k3220.htm",
      "contextRef": "D2020Q1KFiling",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Contained File Information, File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ptcbio.com/role/CoverPageDocument"
     ],
     "xbrltype": "booleanItemType"
    },
    "ptct_CoverpageAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "cover page [Abstract]",
        "label": "cover page [Abstract]"
       }
      }
     },
     "localname": "CoverpageAbstract",
     "nsuri": "http://www.ptcbio.com/20200302",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>a8k3220_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ptct-20200302.xsd" xlink:type="simple"/>
    <context id="D2020Q1KFiling">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2020-03-02</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="D2020Q1KFiling"
      id="Fact-6D78E7AB917A57E9A2E85AB742DFEA07-wk-Fact-6D78E7AB917A57E9A2E85AB742DFEA07">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="D2020Q1KFiling"
      id="Fact-7071B806971650D9A871936480C7428D-wk-Fact-7071B806971650D9A871936480C7428D">0001070081</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="D2020Q1KFiling"
      id="d20668387e67-wk-Fact-B18B5CE5D71C551DA44A69A3F623395A">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="D2020Q1KFiling"
      id="d20668387e81-wk-Fact-E1EC99EFAD5D58B982D77FDFDA94967F">2020-03-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="D2020Q1KFiling"
      id="d20668387e86-wk-Fact-4DE17A506E435C37ABCD3C1ECE5DDE15">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="D2020Q1KFiling"
      id="d20668387e110-wk-Fact-AEA456BE93355868A0C8DE43E59EBBC9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="D2020Q1KFiling"
      id="d20668387e120-wk-Fact-D7701235B12E5B999ADCEE19496A3180">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="D2020Q1KFiling"
      id="d20668387e130-wk-Fact-1E8231B4EBAA5AEE9B20F7E6BB3D14B0">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="D2020Q1KFiling"
      id="d20668387e182-wk-Fact-B6C8ACEE72F7534B8B079F4472FFD4B9">100 Corporate Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="D2020Q1KFiling"
      id="d20668387e203-wk-Fact-6F60D21B60C455479FF1C786AC9DA904">South Plainfield,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="D2020Q1KFiling"
      id="d20668387e208-wk-Fact-9A78F8479897528F82DA5F72541C944D">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="D2020Q1KFiling"
      id="d20668387e218-wk-Fact-22A36917E7C955848CF9ABFF6EEC404E">07080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="D2020Q1KFiling"
      id="d20668387e245-wk-Fact-9D90CE8BD8D2508C930BF4BD6197F184">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="D2020Q1KFiling"
      id="d20668387e249-wk-Fact-B1B28B305BE95501B8E3DE256639F1A6">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="D2020Q1KFiling"
      id="d20668387e270-wk-Fact-8E17077AC39A53B1BB113D011F506C35">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="D2020Q1KFiling"
      id="d20668387e280-wk-Fact-E2C63CB69F015071BCCFDC73E4D6BC1C">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="D2020Q1KFiling"
      id="d20668387e290-wk-Fact-B95F170873B357FB8F5A42883DFF0862">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="D2020Q1KFiling"
      id="d20668387e300-wk-Fact-A01D2E79710150F7937320A117BD807D">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="D2020Q1KFiling"
      id="d20668387e342-wk-Fact-08CA5F71A7BB53B8A32A3F88BBC124D7">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="D2020Q1KFiling"
      id="d20668387e347-wk-Fact-D021CCE5738A5FA288AA3E1C3223AC43">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="D2020Q1KFiling"
      id="d20668387e352-wk-Fact-8F82BBB8D17A5620B169A0E100B0E036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="D2020Q1KFiling"
      id="d20668387e362-wk-Fact-5427347A88EA5F32B51FEE3E7B40B3B9">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
